PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Enfortumab Vedotin→

Enfortumab Vedotin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1346452-25-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Nectin-4-directed antibody–drug conjugate (ADC)microtubule-disrupting antineoplastic
Mechanism of action
The antibody binds Nectin-4 on tumour cells and is internalised. Intracellular cleavage releases monomethyl auristatin E (MMAE), a microtubule-disrupting agent that inhibits cell division and induces apoptosis.
Indications / reported uses
  • Treatment of adults with locally advanced or metastatic urothelial cancer in combination with pembrolizumab as first-line therapy under the current US product indication
  • Treatment of adults with locally advanced or metastatic urothelial cancer previously treated with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy, where applicable under the product label

Sources: US DailyMed — PADCEV (enfortumab vedotin-ejfv) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Enfortumab Vedotin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Enfortumab Vedotin Permitted Daily Exposure (PDE) report (the Enfortumab Vedotin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Enfortumab Vedotin Occupational Exposure Limit (OEL) report (the Enfortumab Vedotin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.